Dual-Peptide PAMAM Dendrimer Conjugates for Enhanced Cell Uptake via E-Selectin Targeting.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• E-selectin is overexpressed on tumor vasculature endothelial cells, indicating potential for targeted delivery.
• Nanocarriers offer a platform for specific targeting of the tumor microenvironment.
• Developing novel nanocarriers with E-selectin-mediated uptake is crucial for advanced cancer therapy.

Purpose of the Study:

• To develop and characterize dual-peptide PAMAM dendrimer conjugates as novel nanocarriers for E-selectin-targeted cancer therapy.
• To evaluate the safety, E-selectin-mediated uptake, and drug delivery capabilities of these nanocarriers.

Main Methods:

• Fourth-generation PAMAM dendrimers were partially acetylated and conjugated with E-selectin targeting peptides (CIELLQAR or CIELFQAR) and pTAT cell-penetrating peptide.
• Acetylation degree and peptide substitution ratios were confirmed using NMR analysis.
• In vitro studies assessed cytotoxicity, E-selectin-mediated uptake in endothelial and tumor cells, and doxorubicin delivery.

Main Results:

• Dual-peptide dendrimer conjugates were successfully synthesized with controlled acetylation and peptide conjugation.
• The nanocarriers exhibited excellent safety profiles with negligible cytotoxicity.
• E-selectin-mediated uptake was confirmed in E-selectin-overexpressing endothelial cells, with pTAT-CIELFQAR showing superior performance.
• The nanocarriers were internalized by T98G tumor cells and demonstrated doxorubicin delivery capabilities.

Conclusions:

• Dual-peptide PAMAM dendrimer conjugates represent a novel and safe nanocarrier system for E-selectin-targeted cancer therapy.
• The pTAT-CIELFQAR conjugated dendrimer demonstrated efficient tumor cell internalization and drug delivery potential.
• This functional dendrimer conjugate platform holds promise for developing targeted cancer therapeutics.